Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Details) - Schedule of antidilutive securities excluded from computation of earnings per share

v3.22.2.2
Net Loss Per Share (Details) - Schedule of antidilutive securities excluded from computation of earnings per share - shares
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Schedule of antidilutive securities excluded from computation of earnings per share [Abstract]        
Options to purchase common stock 1,177,104 660,921 1,177,104 660,921
Warrants to purchase common stock 4,784,193 4,784,193
Total 5,961,297 660,921 5,961,297 660,921